<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171754</url>
  </required_header>
  <id_info>
    <org_study_id>1200.79</org_study_id>
    <nct_id>NCT02171754</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of a Single-dose Administration of BIBW 2992 and Multiple-dose Administration of Ritonavir in Healthy Volunteers</brief_title>
  <official_title>Relative Bioavailability of a Single Oral Dose of BIBW 2992 (20 mg) After Coadministration With Multiple Oral Doses of Ritonavir (200 mg Bid for 3 Days) Compared to the Bioavailability of a Single Oral Dose of BIBW 2992 (20 mg) Alone in Healthy Male Volunteers (an Open-label, Randomised, Two-way Crossover, Clinical Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective was to investigate the effect of ritonavir, an inhibitor of P-glycoprotein
      (P-gp) and cytochrome P450 3A4 (CYP3A4), on the pharmacokinetics of BIBW 2992
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to infinity) - BIBW 2992</measure>
    <time_frame>up to 6 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) - BIBW2992</measure>
    <time_frame>up to 6 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma) - BIBW 2992</measure>
    <time_frame>up to 6 days after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 hours) - BIBW 2992</measure>
    <time_frame>up to 6 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCtz-∞ (percentage of the AUCtz-∞ that is obtained by extrapolation from the last quantifiable data point to infinity) - BIBW 2992</measure>
    <time_frame>up to 6 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte in plasma) - BIBW 2992</measure>
    <time_frame>up to 6 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant in plasma) - BIBW 2992</measure>
    <time_frame>up to 6 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte in plasma) - BIBW 2992</measure>
    <time_frame>up to 6 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo (mean residence time of the analyte in the body after oral administration) - BIBW 2992</measure>
    <time_frame>up to 6 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of the analyte in the plasma after extravascular administration) - BIBW 2992</measure>
    <time_frame>up to 6 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) - BIBW 2992</measure>
    <time_frame>up to 6 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal findings in physical examination</measure>
    <time_frame>Screening, up to 20 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)</measure>
    <time_frame>Screening, up to 20 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>Screening, up to 20 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 41 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>Screening, up to 20 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>up to 20 days after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBW 2992 + Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBW 2992</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBW 2992</intervention_name>
    <arm_group_label>BIBW 2992 + Ritonavir</arm_group_label>
    <arm_group_label>BIBW 2992</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>BIBW 2992 + Ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males according to a complete medical history, including a physical
             examination, vital signs (blood pressure, pulse rate), 12-lead Electrocardiogram
             (ECG), and clinical laboratory tests

          -  Age 21 to 55 years, inclusive

          -  Body mass index 18.5 to 29.9 kg/m2, inclusive

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation

        Exclusion Criteria:

          -  Any finding of the medical examination (including Blood Pressure (BP), Pulse Rate (PR)
             and Electrocardiogram (ECG)) deviating from normal and of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts 7. Chronic
             or relevant acute infections (e.g. HIV)

          -  History of relevant allergy/hypersensitivity (including drug allergy or its
             excipients)

          -  Intake of drugs with a long half-life (&gt;24 hours) within 1 month prior to
             administration of the trial drug or during the trial

          -  Use of any drugs (including herbal preparations, vitamins and nutrient supplements)
             within 14 days prior to first administration of the trial drug or during the trial

          -  Participation in another trial with an investigational drug within 2 months prior to
             administration or during the trial

          -  Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day)

          -  Inability to refrain from smoking within the in-house periods from 12 hours before
             until 25 hours after each administration of the trial drug

          -  Alcohol abuse (more than 30 g/day)

          -  Drug abuse

          -  Blood donation (more than 100 mL within 4 weeks prior to administration of the trial
             drug or during the trial)

          -  Excessive physical activities (within 1 week prior to administration of the trial drug
             or during the trial)

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of trial site

          -  A marked baseline prolongation of QT/QTc interval (e.g. repeated demonstration of a
             QTc interval &gt;450 ms)

          -  A history of additional risk factors for Torsades de Points, e.g. heart failure,
             hypokalemia, family history of Long QT Syndrome

        Exclusion criteria specific for this study:

          -  History of clinically relevant skin diseases, psoriasis or moderate/severe acne

          -  History or evidence of interstitial lung disease

          -  Males who are unwilling to use a medically acceptable method of contraception during
             the first 3 months after administration of BIBW 2992. Acceptable methods of
             contraception for use by male volunteers include sexual abstinence, a vasectomy
             performed at least 1 year prior to dosing, barrier contraception or another medically
             accepted contraceptive method
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

